10x Genomics Q3 revenue $125.3M (+74% YoY); FY2021 guidance raised to $490-500M

10x Genomics, Inc.

2021-Q3 EPS reported -$0.36 revenue$346,960,000

Revenue $125.3M, up 74% YoY and 8% QoQ; operating loss $15.9M vs $65.3M loss last year.
Gross margin flat at 80%; net loss $17.2M vs $65.8M loss Q3 2020.
Cash $600.4M; began shipping Chromium X instrument.
FY2021 revenue guidance revised to $490-500M (64-67% growth over FY2020).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.